The annual global economic burden of heart failure

https://doi.org/10.1016/j.ijcard.2013.12.028Get rights and content

Abstract

Background

Heart failure (HF) imposes both direct costs to healthcare systems and indirect costs to society through morbidity, unpaid care costs, premature mortality and lost productivity. The global economic burden of HF is not known.

Methods

We estimated the overall cost of heart failure in 2012, in both direct and indirect terms, across the globe. Existing country-specific heart failure costs analyses were expressed as a proportion of gross domestic product and total healthcare spend. Using World Bank data, these proportional values were used to interpolate the economic cost of HF for countries of the world where no published data exists. Countries were categorized according to their level of economic development to investigate global patterns of spending.

Results

197 countries were included in the analysis, covering 98.7% of the world's population. The overall economic cost of HF in 2012 was estimated at $108 billion per annum. Direct costs accounted for ~ 60% ($65 billion) and indirect costs accounted for ~ 40% ($43 billion) of the overall spend. Heart failure spending varied widely between high-income and middle and low-income countries. High-income countries spend a greater proportion on direct costs: a pattern reversed for middle and low-income countries.

Conclusions

Heart failure imposes a huge economic burden, estimated at $108 billion per annum. With an aging, rapidly expanding and industrializing global population this value will continue to rise.

Introduction

In nearly all regions of the world HF is both common and increasing [1], [2]. Although death rates from cardiovascular disease (CVD) as a whole have declined, HF is the only major CVD whose prevalence and incidence are thought to be increasing [3] and the long-term prognosis associated with HF is poor [4].

As the global problem of HF increases, there is also the significant economic burden of disease to be considered. It is increasingly important for governments and health organizations to have an estimate of the costs attributed to HF, as they will have to plan, predict and finance the care of a rapidly growing and aging global population.

The economic impact of a disease is considered in terms of direct and indirect costs. Direct costs include healthcare expenditure on hospital services, medications, physician costs, primary healthcare costs and follow-up. Indirect costs include healthcare expenditure in terms of lost productivity resulting from morbidity and mortality, sickness benefit and welfare support.

Although some data on the prevalence and cost of HF exists, this is scarce and largely limited to the high-income countries of Western Europe and North America. There is almost a complete lack of data regarding middle to low-income countries, despite the fact they represent over 80% of the world's population.

The objective of this study was to calculate, from available information, a best estimate of the overall cost of HF per annum, in both direct and indirect terms, across the globe.

Section snippets

Direct and indirect HF costs sources

A literature review of studies assessing the crude prevalence rates and economic burden of HF was performed using the MEDLINE database. The terms heart failure, myocardial failure, congestive heart failure and medical subject headings economics, statistics and numerical data were used and abstracts reviewed for relevance (Fig. 1).

In addition, data from government department of health documents, professional society reports and non-profit organization reports were included and referenced

Statistics

Where relevant, comparisons between mean values of groups were made using the Student paired t test. A p value < 0.05 was pre-defined as statistically significant.

Data sources

13 published economic estimates of healthcare costs attributed specifically to HF were included in the study. Only 1 source (American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart Disease and Stroke Statistics Report, 2013) included indirect HF costs [9] (Table 1). Study estimates spanned a range of 22 years. The earliest economic estimate was from 1990 and the latest 2012.

Published economic estimates were predominantly from the USA, Europe and Australasia, with

Discussion

HF is a common problem, affecting between 1–2% of the population [16]. It represents a growing global health problem that will reach epidemic proportions in an ageing and rapidly expanding global population. Currently, the crude prevalence rate of HF in high-income countries is greater than in the economically developing world [9], [16], [21], [22], [23], [24], [25], [26], though reporting bias may contribute to this. In high-income countries HF is most commonly the consequence of a composite

Study limitations

Despite efforts made to utilize the available published data resourcefully, there are limitations in this study. Fundamentally, the values provided are only estimates of economic burden based on best available information. The existing published economic dataset has very limited global representation with a heavy bias towards data from high-income countries. In particular, no economic HF data exists in WDI defined low-income countries, and so middle and low-income countries have been

Conclusions

This study defines the global economic impact of HF. It provides a benchmark value intended to develop understanding of the impact of HF outside of the conventional framework of mortality and morbidity.

It provides new information, especially relevant in a rapidly changing global economic landscape, highlighting the burden of disease in middle and low-income countries. For the first time it provides economic estimates aimed at these regions, where epidemiological and economic data currently do

References (45)

  • A.S. Go et al.

    Heart disease and stroke statistics—2013 update: a report from the American Heart Association

    Circulation

    (2013 Jan 1)
  • T. Neumann et al.

    Heart failure: the commonest reason for hospital admission in Germany

    Dtsch Arztebl Int

    (2009 Apr)
  • S. Stewart et al.

    The current cost of heart failure to the National Health Service in the UK

    Eur J Heart Fail

    (2002 Jun)
  • F.M. Albanesi Filho

    What is the current scenario for heart failure in Brazil?

    Arq Bras Cardiol

    (2005 Sep)
  • B. Agvall et al.

    Cost of heart failure in Swedish primary healthcare

    Scand J Prim Health Care

    (2005 Jan)
  • F. Antoñanzas Villar et al.

    Costs of chronic heart failure in Spain

    An Med Interna

    (1997 Jan)
  • C. Berry et al.

    Economics of chronic heart failure

    Eur J Heart Fail

    (2001 Jun 1)
  • M. Czech et al.

    The costs of heart failure in Poland from the public payer's perspective. Polish programme assessing diagnostic procedures, treatment and costs in patients with heart failure in randomly selected outpatient clinics and hospitals at different levels of car. Kardiologia Polska

    Pol Heart J

    (2013 Mar 21)
  • C. Mathers et al.

    Health system costs of cardiovascular diseases and diabetes in Australia 1993–94. Health and welfare expenditure series no. 5. Cat. no. HWE 11

    (1999)
  • W.J. Meerding et al.

    Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study

    BMJ

    (1998 Jul 11)
  • N. Claes et al.

    Impact of heart failure on hospital activity and healthcare costs in Belgium

    J Med Econ

    (2008)
  • Australian Bureau of Statistics

    Data retrieved December 1, 2012, from National Health Survey: Summary of results. 436 4.0. 2004–05

  • Cited by (639)

    View all citing articles on Scopus
    View full text